• Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

    1 month ago - By Xconomy

    Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the science speak for itself. Since it was founded five years ago, the company has moved three compounds into the clinic. How? By operating under the radar. “If you take away the outside distractions, which is what we've been doing; when you have that singular focus, which is to develop drugs, it really helps,” Zentalis Pharmaceuticals CEO Anthony Sun tells Xconomy. The company this week emerged from “stealth mode” after...
    Read more ...